Related references
Note: Only part of the references are listed.Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study)
Jennifer A. Brown et al.
HIV MEDICINE (2022)
Dolutegravir Resistance in Malawi's National HIV Treatment Program
Joep J. van Oosterhout et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
Claire M. Keene et al.
AIDS (2021)
Dolutegravir drug-resistance monitoring in Africa
Vinie Kouamou et al.
Lancet HIV (2021)
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey
Anne-Genevieve Marcelin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV
Nicholas I. Paton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Emergent Resistance to Dolutegravir Among INSTI-Naive Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
Muge Cevik et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries
Seth C. Inzaule et al.
AIDS (2020)
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens
Seth C. Inzaule et al.
LANCET INFECTIOUS DISEASES (2019)
A systematic review of the genetic mechanisms of dolutegravir resistance
Soo-Yon Rhee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
Marco Vitoria et al.
AIDS (2018)
Dolutegravir resistance mutations: lessons from monotherapy studies
Jose L. Blanco et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2018)
The fourth HIV epidemic
Gabriele Laborde-Balen et al.
LANCET INFECTIOUS DISEASES (2018)
The unexpected success of NRTIs in second-line treatment
Andrew M. Hill et al.
LANCET INFECTIOUS DISEASES (2018)
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
Andrew N. Phillips et al.
LANCET HIV (2018)
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
Jienchi Dorward et al.
LANCET HIV (2018)
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa
Andrew N. Phillips et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
HIV Drug Resistance - An Emerging Threat to Epidemic Control
Chris Beyrer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
John Gregson et al.
LANCET INFECTIOUS DISEASES (2016)
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Steve Kanters et al.
LANCET HIV (2016)
Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia
Marjorie Monleau et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Masanori Kobayashi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations
J Deval et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Share Paper
